U.S. companies continue to grow through mergers and acquisitions as Canada consolidates
The graph displays the total consideration for M&A transactions in the United States and Canada since 2019.
In Q1: 21, activity in both countries soared. Business in the United States benefited from an increase in acquisitions of public companies including Liberty Health, Helix TCS and Bluma Wellness. The Canadian operations included a sale of $ 353 million to Canopy Growth of its stake in Canopy Rivers.
While consolidation among Canadian limited partnerships seeking positive cash flow is likely to continue, we expect the higher growth potential of the US market to keep US targets at the forefront of M&A activity.
The Viridian Capital Chart of the Week highlights key investment, valuation, and M&A trends from the Viridian Cannabis Deal Tracker.
The Viridian Cannabis Deal Tracker is a proprietary information service that monitors capital raising and mergers and acquisitions in the legal cannabis and hemp industry. Each week, the Tracker aggregates and analyzes all the transactions concluded and each segment according to key metrics:
Industry sector (one of 12 sectors, from culture to brands)
Dollar value of the transaction
Region in which the transaction took place (country or US state)
Status of the company announcing the transaction (Public vs. Private)
Structure of the transaction (equities vs debt)
Key terms of the transaction (pricing and evaluation)
The Viridian Cannabis Deal Tracker provides the market information that cannabis companies, investors and acquirers use to make informed decisions regarding capital allocation and M&A strategy.
Since its inception in 2015, Viridian Cannabis Deal Tracker has tracked and analyzed over 2,500 capital raisings and 1,000 M&A transactions totaling over $ 50 billion in aggregate value.
The previous article is from one of our external contributors. It does not represent Benzinga’s opinion and has not been edited.
Encuentra nuestro contenido en Español and El Planteo:
See more Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.